WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Antimicrobial Study of Manahshila: A Comprehensive Exploration of Its Traditional and Scientific Relevance

[1]Dr. Sohan Lal Saini, [2]Dr. Arun Kumar Das

[1]Ph.D Scholar, Department Of Rasa Shastra and Bhaishjya Kalpana, Gopabandhu Ayurveda Mahavidyalaya, Puri (Odisha)
[2]Principal, Gopabandhu Ayurveda Mahavidyalaya, Puri (Odisha)

ABSTRACT

Manahshila, also known as realgar (arsenic disulfide, As_2S_2), is a mineral-based compound integral to Ayurvedic medicine for centuries. Traditionally valued for its therapeutic properties, particularly in treating skin disorders and infections, Manahshila has recently garnered attention in modern scientific research for its potential antimicrobial activity. This article provides an in-depth analysis of Manahshila's antimicrobial properties, bridging traditional Ayurvedic knowledge with contemporary scientific studies. It explores its chemical composition, historical uses, preparation methods, pharmacological mechanisms, and recent research findings, while critically examining its efficacy, safety, and challenges in antimicrobial applications. The article also discusses the global antimicrobial resistance (AMR) crisis and positions Manahshila as a potential alternative or complementary therapeutic agent.

KEY WORDS- Manahshila, realgar, efficacy, safety, and antimicrobial applications etc.

INTRODUCTION

The escalating global crisis of antimicrobial resistance (AMR) has driven researchers to explore alternative therapeutic agents, including those derived from traditional medicinal systems like Ayurveda. According to the World Health Organization, AMR contributes to approximately 1.27 million deaths annually, with projections estimating 10 million deaths per year by 2050 if unaddressed. Conventional antibiotics are increasingly ineffective against multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, necessitating novel antimicrobial solutions. Ayurveda, an ancient Indian medicinal system, offers a repository of natural compounds, including mineral-based formulations like Manahshila, which have been used for their antimicrobial and therapeutic properties.

Manahshila, or realgar, is a naturally occurring arsenic sulfide mineral historically employed in Ayurveda for its Krimighna (antimicrobial) and Kushthaghna (anti-skin disease) properties. Incorporated into formulations such as Manahshiladi Lepa and Shila Sindura, it has been traditionally used to treat skin infections, fungal diseases, and other microbial conditions. Recent scientific studies have begun to validate these traditional claims, investigating Manahshila's efficacy against gram-positive and gram-negative bacteria, as well as fungi. This article aims to synthesize traditional knowledge with modern research, providing a comprehensive overview of Manahshila's antimicrobial potential, its mechanisms, and the challenges associated with its use.

HISTORICAL AND TRADITIONAL CONTEXT OF MANAHSHILA

- **Manahshila in Ayurveda**

In Ayurvedic texts, such as the Charaka Samhita and Sushruta Samhita, Manahshila is described as a potent mineral drug with specific therapeutic attributes. It is classified as a Rasaushadhi (mineral-based medicine) and is valued for its ability to balance Kapha and Vata doshas, which are associated with conditions like fungal infections and skin disorders. Manahshila is often combined with other ingredients, such as sulfur (gandhaka), mercury (parada), or herbal extracts, to enhance its efficacy and reduce toxicity.

Traditional indications for Manahshila include:

Kushtha: Skin disorders, including fungal and bacterial infections.

Kandu: Itching associated with microbial infections.

Jwara: Fevers of infectious origin.

Vidradhi: Abscesses caused by bacterial infections.

Upadamsha: Conditions resembling gonorrhea.

Ayurvedic preparations like Manahshiladi Lepa (a topical paste) and Shila Sindura (a processed formulation) utilize Manahshila for its antimicrobial and anti-inflammatory properties. These preparations undergo meticulous processing (Shodhana and Marana) to detoxify the mineral and enhance its therapeutic potential.

❖ **Preparation of Manahshila in Ayurveda**

The preparation of Manahshila follows strict Ayurvedic protocols to ensure safety and efficacy. Raw Manahshila, being an arsenic compound, is toxic and requires purification (Shodhana) to remove impurities and reduce toxicity. Common purification methods include:

Soaking in herbal decoctions (e.g., ginger juice or Triphala decoction) to neutralize toxic elements.Grinding with specific herbs to enhance bioavailability. Heating or calcination (Marana) to convert the mineral into a bioavailable form. For example, in Shila Sindura, Manahshila is combined with mercury and sulfur, processed in a Kupipakwa method (heating in a glass bottle), resulting in a fine, bioavailable powder used in doses of 125–250 mg. These processes are believed to transform Manahshila into a safe and effective antimicrobial agent.

Chemical Composition and Pharmacological Properties

❖ **Chemical Composition**

Manahshila is primarily arsenic disulfide (As_2S_2), a red-orange crystalline mineral. Its chemical structure consists of covalent As–S bonds, which contribute to its stability and reactivity. Trace elements, such as iron or sulfur compounds, may be present depending on the source of the mineral. The antimicrobial activity of Manahshila is attributed to the release of arsenic ions, which disrupt microbial cell processes, and sulfur, which enhances its efficacy against certain pathogens.

❖ **Pharmacological Properties**

Manahshila's pharmacological properties in Ayurveda are described in terms of its Rasa (taste), Guna (qualities), Veerya (potency), and Vipaka (post-digestive effect):

S.N	Property	Characteristic
1.	Rasa	Bitter (Tikta) and astringent (Kashaya), contributing to its detoxifying and antimicrobial effects.
2.	Guna	Light (Laghu) and dry (Ruksha), aiding in topical applications.
3.	Veerya	Hot (Ushna), enhancing its antimicrobial and anti-inflammatory actions.
4.	Vipaka	Pungent (Katu), supporting its role in combating infections.

These properties align with Manahshila's traditional use in treating microbial infections, particularly those involving Kapha and Vata imbalances.

Antimicrobial Mechanisms of Manahshila

Review of Experimental Studies

1. In vitro Antibacterial Activity

Methodology: Agar well diffusion method

Organisms Tested: E. coli, S. aureus, Pseudomonas aeruginosa

Result: Significant zone of inhibition observed, especially against Gram-positive strains

Conclusion: Manashila Bhasma exhibited dose-dependent antibacterial action.

2. Antifungal Activity

Tested against Candida albicans and Aspergillus niger

Moderate inhibition at low concentration

Synergistic effects when used with other antifungal herbs like Neem or Haridra

3. Antiviral Prospects

Though not widely studied, certain arsenic-based compounds have shown potential in inactivating viral RNA. Traditional use of Manashila in diseases with possible viral etiology (e.g., fever, skin eruptions) suggests antiviral potential worth exploring further.

The antimicrobial activity of Manahshila is mediated through several mechanisms, inferred from its chemical composition and traditional applications:

Disruption of Microbial Cell Membranes: Arsenic ions interfere with microbial cell membrane integrity, leading to leakage of cellular contents and cell death.

Inhibition of Enzymatic Activity: Arsenic compounds inhibit key microbial enzymes, such as those involved in energy metabolism, disrupting cellular processes.

Reactive Oxygen Species (ROS) Generation: Manahshila may induce oxidative stress in microbial cells, causing damage to DNA, proteins, and lipids.

Synergistic Effects with Sulfur: In formulations like Shila Sindura, sulfur enhances antimicrobial activity by targeting sulfur-containing proteins in microbial cells.

These mechanisms make Manahshila effective against a broad spectrum of pathogens, including gram-positive bacteria (e.g., Staphylococcus aureus), gram-negative bacteria (e.g., Escherichia coli), and fungi (e.g., Candida albicans).

Recent Research on Manahshila's Antimicrobial Activity

- **Shila Sindura Studies**

A 2024 study published on ResearchGate investigated the antimicrobial activity of Shila Sindura, a Kupipakwa Rasayana preparation containing Manahshila, mercury, and sulfur. The study tested its efficacy against gram-positive (S. aureus), gram-negative (E. coli, Klebsiella pneumoniae), and fungal (Candida albicans) pathogens using in vitro assays. Key findings include:

Broad-Spectrum Activity: Shila Sindura exhibited significant antimicrobial activity against all tested pathogens, with minimum inhibitory concentrations (MICs) comparable to standard antibiotics in some cases.

Safety Profile: Toxicological studies in rats (250 mg/kg for 14 days) showed no significant changes in body weight, blood parameters, or liver/kidney histology, suggesting safety when properly processed.

Mechanism: The study hypothesized that the synergistic effects of arsenic and sulfur compounds disrupted microbial cell membranes and metabolic pathways.

- **Manahshiladi Lepa Studies**

A review article in the World Journal of Pharmaceutical Research (2024) explored the efficacy of Manahshiladi Lepa, a topical formulation containing Manahshila, Hartala (orpiment), Maricha (black pepper), Sarshapa Taila (mustard oil), and Arka Kshira (Calotropis procera latex). The study focused on its use against fungal infections, particularly those caused by Candida albicans. Key findings include:

Antifungal Efficacy: The formulation showed potent antifungal activity, with Manahshila and Hartala contributing Krimighna properties and Arka Kshira targeting Candida albicans.

Kapha-Vatahara Action: The ingredients collectively balanced Kapha and Vata doshas, reducing fungal tissue lysis and promoting skin healing.

Clinical Relevance: The review suggested Manahshiladi Lepa as a viable alternative for treating chronic fungal skin infections, especially in regions with high prevalence (e.g., 27.6% of India's population affected by superficial fungal infections).

- **Comparative Studies**

Comparative studies have evaluated Manahshila against other natural antimicrobial agents. For instance, a study on neem (Azadirachta indica) extracts and silver nanoparticles (Ag-NPs) found that while neem showed significant antimicrobial activity, Manahshila-based formulations like Shila Sindura had comparable or superior efficacy against certain gram-negative bacteria. This suggests that Manahshila's mineral-based composition may offer unique advantages over plant-based antimicrobials.

Ayurvedic Formulations Containing Manashila

1. Rasa Manikya

2. Kasisadi Taila – used for skin infections

3. Manashiladi Vati – Krimighna action

4. Krimimudgar Rasa – Anthelmintic and antibacterial

Comparison with Conventional Antibiotics

Parameter	Manashila	Modern Antibiotics
Spectrum	Broad (in Ayurveda)	Specific or broad
Resistance	Rare reports	Increasing resistance
Toxicity	High if unprocessed	Dose-dependent
Cost	Low	Moderate to high
Sustainability	High	Depends on synthesis process

Challenges and Safety Concerns

- **Toxicity of Arsenic**

Manahshila's primary component, arsenic disulfide, is inherently toxic, raising concerns about its safety in therapeutic applications. Acute arsenic toxicity can cause nausea, vomiting, and organ damage, while chronic exposure is linked to carcinogenicity. Ayurvedic processing methods (Shodhana) aim to mitigate these risks, but improper preparation or overuse can lead to adverse effects. Modern studies emphasize the need for standardized protocols to ensure safety.

- **Regulatory Challenges**

The use of arsenic-based compounds in medicine is heavily regulated in many countries due to toxicity concerns. In India, Ayurvedic formulations are regulated under the Drugs and Cosmetics Act, 1940, but global acceptance requires rigorous clinical trials and safety data. The lack of standardized quality control for Manahshila-based preparations poses a barrier to its integration into modern medicine.

- **Limited Clinical Data**

While in vitro studies demonstrate Manahshila's antimicrobial potential, clinical trials are scarce. The transition from laboratory to clinical settings requires extensive research to validate efficacy, determine optimal dosages, and assess long-term safety.

Manahshila in the Context of AMR

The global AMR crisis underscores the need for alternative antimicrobial agents. Manahshila's broad-spectrum activity and unique mechanisms (e.g., ROS generation, enzyme inhibition) make it a candidate for combating MDR pathogens. Unlike conventional antibiotics, which target specific bacterial pathways (e.g., cell wall synthesis), Manahshila's multifaceted action may reduce the likelihood of resistance development. However, its integration into modern therapeutics requires:

Combination Therapies: Combining Manahshila with existing antibiotics or herbal agents could enhance efficacy and reduce toxicity.

Nanotechnology: Encapsulating Manahshila in nanoparticles, similar to neem-derived Ag-NPs, could improve delivery and reduce systemic toxicity.

AI-Driven Drug Development: Artificial intelligence can optimize Manahshila-based formulations by predicting effective combinations and dosages.

Future Directions

Research Priorities

Clinical Trials: Conduct randomized controlled trials to evaluate Manahshila's efficacy and safety in human subjects.

Mechanistic Studies: Elucidate the molecular mechanisms of Manahshila's antimicrobial action using advanced techniques like proteomics and metabolomics.

Standardization: Develop standardized protocols for Manahshila preparation to ensure consistency and safety.

Integration with Modern Medicine

Integrating Manahshila into modern antimicrobial strategies requires collaboration between Ayurvedic practitioners, pharmacologists, and regulatory bodies. Public-private partnerships, such as those with the Global Antibiotic Research & Development Partnership (GARDP), could facilitate research and development.

Public Health Implications

Manahshila-based formulations could address AMR in low- and middle-income countries, where access to novel antibiotics is limited. Their cost-effectiveness and local availability make them viable for community-level interventions, particularly for skin infections and diarrheal diseases.

Conclusion

Manahshila represents a fascinating intersection of traditional wisdom and modern science. Its antimicrobial properties, validated by recent studies, highlight its potential as an alternative therapeutic agent in the face of rising AMR. However, challenges related to toxicity, regulatory acceptance, and clinical validation must be addressed to realize its full potential. By combining Ayurvedic knowledge with cutting-edge research, Manahshila could contribute to innovative solutions for global health challenges, offering hope in the fight against resistant pathogens.

REFERENCES:

1. Sharma, Bagawandash, editors. 5 th ed. Varanasi: Chaukamba Sanskrit Series; 2003. Kustha adhyaya , 7/117-118.p. 349.
2. Vagbhata. Astanga Hrdayam, Vol. I. Shrikanta Murthy, editor. 5 th ed. Varanasi: Chaukamba Sanskrit Series; 1991. Dhoomapana vidhi adhyaya, 21/18.p. 267.
3. Raja Radhakant Deb, Bahadur. Shabda Kalpa Druma, Vol. 3. 8 th ed. Varanasi: Chaukambha Sanskrit series office; 2002.p.524.
4. Gulraj Sharma. Ayurveda Prakasa. 2 nd ed. Varanasi: Chaukambha Sanskrit Series Office; 1999.p.213 -224.
5. Kasinath Shastri. Rasa Tarangini. 11th ed. Varanasi: Motilal Banarasidas; 2000: Atha talakadi vignaneeya namadhyaya. p.262.
6. Damodar Joshi. Rasamritam. 2nd ed. Varanasi: Chaukambha Sanskrit Series Office; 2003.p.12.
7. Vilas Dole, Prakash Paranjpe. Text Book of Rasashastra. 1 st ed. Varanasi: Chaukambha Sanskrit Prathishtan; 2006.p.239.
8. Sadaananda Sharma. Rasa Tarangini. 5th ed. Varanasi: Chaukamba Sanskrit Series Office; 1983.p.108 -129.
9. Vishwanath Dwivedi. Bharatiya Rasashastra. 2 nd ed. Varanasi: Shri Sharma Ayurveda Mandir; 2000.p.306.
10. Ambika Datta Shastri. Rasaratna Samuchayam. 3rd ed. Varanasi: Chaukamba Sanskrit Series; 1961. Atha uparasanam namami adhyaya, 3/96.p.75-76.
11. Chakravorty P. Text Book of Microbiology. 2 nd ed. Kolkata: New Central Book Agency; 2006.p.238, 316, 644.
12. Goodman and Gillman. The Pharmacological basis of Therapeutics. 9th ed. New York: Mcgraw-Hill (Tx); 1996. Ch. 66.